Kura Oncology reports Q3 EPS (85c), consensus (68c)

Reports Q3 revenue $20.75M, consensus $46.33M. “Our momentum is accelerating across the ziftomenib program and our broader precision oncology pipeline,” said CEO Troy Wilson. “With the initiation of the pivotal KOMET-017 Phase 3 trials, we are executing a robust, focused development strategy to unlock ziftomenib’s best-in-class potential across the continuum of unmet need in AML. Bolstered by a strong balance sheet and our productive partnership with Kyowa Kirin, we are well positioned to advance ziftomenib toward commercialization, accelerate our frontline Phase 3 trials and create enduring value across our pipeline for patients and other key stakeholders.”